Health groups join patent war over spinal muscular atrophy drug
Wednesday, 6 November 2024
Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Natco Pharma prioritizes profits over patient access to affordable treatment, potentially violating the National Rare Disease Policy.
|
||||
|
|
||||
💡 newsR Knowledge: Other News Mentions
|
||||
Iran to open 'hijab removal treatment clinic' for women who oppose mandatesIran's announcement of a 'treatment facility' for women who violate hijab laws has drawn international condemnation. The facility, intended to provide...IndiaTimes Also reported by •Zee News |
Quack's 'treatment' paralyses 68-year-old woman in TelanganaA woman in Tandur suffered severe health complications after receiving treatment from an unqualified practitioner. The woman experienced sepsis and loss of...IndiaTimes |
National Cancer Awareness Day: Supporting Employees Through Cancer Treatment And RecoveryLearn how employers can support employees navigating cancer treatment and recovery, fostering a compassionate and resilient workplace.Zee News Also reported by •DNA |
